Not all patients with rectal cancer require surgery. This is the conclusion of researchers from Radboud university medical center after they analyzed data from the Netherlands Cancer Registry. Currently, almost all patients with early-stage rectal cancer undergo surgery to remove the tumor, but this appears not to be necessary in all cases. The Radboudumc Center for Oncology has launched an international study into two rectum-conserving treatments. On July 5th, the first Dutch patient was enrolled in this study.In recent years, more and more rectal cancer patients who were treated with radiation and chemotherapy no longer underwent surgery. Surgery can lead to a stoma or problems with defecation, urination and sexual functioning. However, rectum-conserving treatment is still used for only a few patients.
Netherlands Cancer Registry
To determine whether more patients could benefit from rectum-conserving treatment, Radboud university medical center researcher Anouk Rombouts studied data from the Netherlands Cancer Registry (Dutch acronym: NKR). The NKR is a database with reliable, objective data on all cancer patients in the Netherlands. Together with a team of researchers, they determined how many patients with rectal cancer still had tumor tissue following radiotherapy and possible chemotherapy. It turned out that no tumor tissue could be detected in 10% to 20% of the patients.
Because more patients could apparently undergo rectum-conserving cancer treatment, the Radboudumc Center for Oncology has initiated a study to compare the current surgical treatment with two rectum-conserving treatments. Hans de Wilt, professor of Oncological Surgery at Radboud university medical center, explains: “Until now our standard procedure was to perform surgery on rectal cancer patients after radiotherapy, but Anouk Rombouts' study indicates that this is not necessary in all cases. Rectum-conserving treatment therefore appears to be an option for more patients with rectal cancer.”
The international study STARTREC will compare the standard surgical treatment with two rectum-conserving treatments. One of these treatments is a short (one-week) radiotherapy treatment, the other is a longer (five week) period of radiotherapy with additional chemotherapy. Patients with rectal cancer will soon be able to enroll in the study at 12 centers * in the Netherlands. The study will also be conducted in Denmark and England. Hans de Wilt is coordinating the study: “STARTREC aims to answer the question of whether these rectum-conserving treatments are as effective as standard surgery. In addition, we want to determine which of these treatments provides the best short-term and long-term results.”
In addition to the STARTREC study, two other national organ-conserving studies are ongoing: the TESAR study and the Wait-and-See registry. Radboud university medical center is the first academic hospital where patients have the option of enrolling in these three studies.
*Participating centers: Radboudumc, Isala, LUMC, Amphia, Catharina Ziekenhuis, AvL, VUmc, IJsselland Ziekenhuis, MC Leeuwarden, Elisabeth-TweeSteden Ziekenhuis, Diakonessenhuis en Laurentius Ziekenhuis.
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
Royal honours for seven Radboud professors24 April 2020
On Friday 24 April, seven professors from Radboud University and Radboud university medical center received telephone calls from the mayors of their towns informing them that they had been awarded royal honours for their exceptional scientific and social merits.read more
Study on effect of BCG vaccine on coronavirus infection in the elderly21 April 2020
Radboud university medical center and UMC Utrecht are working on a joint research project to discover whether the tuberculosis (BCG) vaccine reduces the risk of infection with the coronavirus in people aged 60 or older, or the severity of the symptoms in the event of infection.read more
Radboudumc researchers publish new insights into COVID-19 Consequences for treatment are now being examined internationally10 April 2020
Researchers at the Radboud university medical center seem to have found an essential mechanism in the disease process of Covid-19, which has so far been overlooked. If the insight is correct, it probably has important consequences for the treatment of the disease.read more
Radboud university medical center and Radboud University collaborate on initiatives in fight against corona Crowdfunding for research and innovations2 April 2020
Help us in our battle against the coronavirus. You have to play a part!read more
Jurgen Fütterer appointed Professor of Image-Guided Oncological Interventions26 February 2020
RIHS researcher Fütterer is an interventional radiologist and an expert in the field of cancer imaging techniques, image-guided interventions and robotics. He is also Professor at the Robotics and Mechatronics Group at the University of Twente.read more
Acute Opname afdeling Radboudumc biedt verlichting in Nijmeegse spoedzorg Snellere doorstroom patiënten Spoedeisende Hulp14 February 2020
Door Acute Opname afdeling patiënten sneller naar de juiste plek.read more